knowledge -WSS

knowledge

author：focus 2025-09-29 01:09:29 - browse：5433

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： A disappointing year of Humira biosimilars

WSS

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Cytokinetics CEO stresses company can launch heart drug on its own

Case highlights the risks of experimental stem cell therapy

What we’ve learned from the Aduhelm mess

Military medical care influenced by rank and race, new study finds

focus

knowledge

explore

Tori Bowie and the unacceptable rates of Black maternal death

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Medical records are filled with copy

Doctors' information doesn't help them choose wisely when sick

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden report: The neurospychology of memory and aging

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Novavax promises a turnaround & Lilly roils the obesity market

Addiction experts warn against a second 'war on drugs'

knowledge

Bird flu: Don't repeat Covid's 'health versus the economy' framing

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Biogen Alzheimer’s drug launch off to slow start

Helping hospitals and community health centers plan for resilience

Venture capitalist Bob Kocher on the state of digital health

Addiction experts warn against a second 'war on drugs'

explore

knowledge

hotspot

hotspot